AG2R LA Mondiale Gestion D Actifs Raises Stock Holdings in Agilent Technologies, Inc. $A

AG2R LA Mondiale Gestion D Actifs lifted its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 12.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,792 shares of the medical research company’s stock after purchasing an additional 1,500 shares during the quarter. AG2R LA Mondiale Gestion D Actifs’ holdings in Agilent Technologies were worth $1,628,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of A. Brighton Jones LLC grew its holdings in shares of Agilent Technologies by 6.1% during the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock worth $626,000 after purchasing an additional 270 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Agilent Technologies by 34.6% during the first quarter. GAMMA Investing LLC now owns 5,362 shares of the medical research company’s stock worth $627,000 after purchasing an additional 1,379 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Agilent Technologies by 3.3% during the first quarter. Sequoia Financial Advisors LLC now owns 35,004 shares of the medical research company’s stock worth $4,095,000 after purchasing an additional 1,106 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its holdings in shares of Agilent Technologies by 2.1% during the first quarter. Robeco Institutional Asset Management B.V. now owns 78,679 shares of the medical research company’s stock worth $9,204,000 after purchasing an additional 1,614 shares in the last quarter. Finally, Bartlett & CO. Wealth Management LLC boosted its stake in Agilent Technologies by 5.1% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 2,406 shares of the medical research company’s stock worth $281,000 after buying an additional 116 shares in the last quarter.

Agilent Technologies Stock Performance

Shares of A stock opened at $148.03 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The stock has a 50 day moving average price of $130.39 and a two-hundred day moving average price of $119.34. The company has a market capitalization of $41.97 billion, a P/E ratio of 34.75, a PEG ratio of 4.83 and a beta of 1.26.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same quarter in the previous year, the company posted $1.32 earnings per share. The business’s revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Analysts expect that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th were issued a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Tuesday, September 30th. Agilent Technologies’s dividend payout ratio is currently 23.24%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Rothschild & Co Redburn assumed coverage on Agilent Technologies in a research note on Wednesday, October 8th. They issued a “buy” rating and a $165.00 target price for the company. Wells Fargo & Company upped their target price on Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, September 15th. Barclays upped their target price on Agilent Technologies from $125.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 2nd. Robert W. Baird upped their target price on Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, August 28th. Finally, Rothschild Redb raised Agilent Technologies to a “strong-buy” rating in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.62.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.